Browsing by Author "Kumar, Viveka"

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    Angiotensin Receptor-Neprilysin Inhibitor Therapy and Cardiac Remodeling in Heart Failure: Consensus Statement from India
    (Association of Physicians of India, 2023-04) Chopra, H K; Wander, G S; Nair, Tiny; Ponde, C K; Nanda, Navin C; Narula, Jagat; Ray, Saumitra; Venugopal, K; Iyengar, S S; Kasliwal, R R; Chandra, Praveen; Prakash, Sunil; Bansal, Sandeep; Rana, D S; Kerkar, Prafulla; Dasbiswas, Arup; Sawhney, JPS; Shanmungasundram, S; Kumar, Viveka; Vijayalakshmi, I B; Pancholia, A K; Sharma, Vinod; Kapoor, Aditya; Swami, Onkar C; Isser, H S; Rastogi, Vishal; Arora, Y K; Omar, Ashok K; Sathe, Sunil; Rajput, Rajeeve; Prabhakar, D; Paul, G Justin; Jagia, Priya; Malhotra, Poonam; Suryaprakash, G; Mittal, Vinod; Jagia, Manish; Jabir, A; Mishra, S, S; Routray, S N; Sinha, Ajay Kumar; Bhargava, Mohan; Mahmood Kiran; Lal, Shreya; Dabhade, Dhammdeep; Bhatia, Mona; Kalra, Pramila; Katyal, V K; Tandon, Rohit; Grover, Rahul; Chhabra, Abhinav; Shastry, N R
    Adverse cardiac remodeling refers to progressive structural and functional modifications in the heart because of increased wall stress in the myocardium, loss of viable myocardium, and neurohormonal stimulation. The guideline-directed medical therapy for Heart failure (HF) includes Angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan), ?-blockers, sodium-glucose co-transporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRA). ARNI is under-prescribed in India despite its attractive safety and efficacy profile. Therefore, the consensus discusses objectives and topics related to ARNI in the management of cardiac remodeling, and experts shared their views on the early timely intervention of effective dosage of ARNI to improve the diagnosis and enhance mortality and morbidity benefits in cardiac reverse remodeling (CRR).
  • Thumbnail Image
    Item
    Are cardiovascular risk parameters and glycemic levels associated with periodontitis in type 2 diabetes patients? A clinical study
    (Cardiological Society of India, 2018-05) Dhir, Sangeeta; Kumar, Viveka
    This study investigated the associations between cardiovascular risk parameters, glycemic level and periodontitis in the diabetic adult population. BMI (body mass index), total cholesterol and triglyceride was used as cardiovascular risk measure and glycosylated hemoglobin (HbA1c) was recorded for glycemic levels. Study results provide evidence of significant association between periodontal disease, cardiovascular risk and glycemic levels.
  • No Thumbnail Available
    Item
    Effectiveness and Safety of the Telmisartan and Amlodipine Fixed-dose Combination in Managing Hypertension among Indian Patients (TACT India Study): Rationale and Study Design
    (Journal of Indian Medical Association, 2024-11) Das, Ashok Kumar; Tiwaskar, Mangesh; Abdullakutty, Jabir; Pande, Arindam; Kumar, Viveka; Zalte, Nitin; Sugumaran, Amarnath; Mohanasundaram, Senthilnathan; Gogtay, Jaideep
    Background: The prevalence of hypertension is on the rise, with approximately 200 million individuals affected by this condition in India. Epidemiological studies suggest that one in every three adults in India has hypertension. Fixed-dose combinations (FDCs) present a potential strategy to address the challenge of effective blood pressure control. They are now recommended for the initiation in most hypertensive patients by the guidelines. However, studies evaluating the safety and effectiveness of FDCs in large Indian populations with hypertension are few. Aim: The aim of this real-world study is to evaluate the safety and effectiveness of the fixed-dose combination of telmisartan and amlodipine in managing hypertension in Indian patients. Materials and methods: This prospective, multicenter, observational, real-world evidence study is designed to enroll 10,000 eligible participants from 1,000 study sites across India. Adult patients with newly diagnosed or uncontrolled hypertension on monotherapy would be eligible for enrollment in the study. The study participants would be administered the study treatment per the treating physician’s routine clinical practice and followed up after 8 weeks. The primary endpoint is to measure the change in systolic blood pressure (SBP) from baseline to week 8, while secondary endpoints include determining the percentage of patients who reach their blood pressure targets., description of demographic characteristics of the Indian hypertensive population, and reporting of safety outcomes. Conclusion: The TACT India study will provide longitudinal, real-world data on the effectiveness and safety of telmisartan and amlodipine FDC among a large cohort of the Indian population with hypertension
  • Thumbnail Image
    Item
    The Power and Promise of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in Heart Failure Management: National Consensus Statement
    (Association of Physicians of India, 2023-02) Chopra, H K; Wander, G S; Ponde, C K; Nanda, Navin C; Khullar, Dinesh; Venugopal, K; Ray, Saumitra; Nair, Tiny; Rana, D S; Kher, Vijay; Sawhney, J P S; Kasliwa, R R; Jabir, A; Chakraborty, Rabin; Chandra, Praveen; Bansal, Sandeep; Kumar, Viveka; Pancholia, A K; Kapoor, Aditya; Prakash, Sunil; Saxena, Anil; Rastogi, Vishal; Sharma, Vinod; Arora, Y K; Dasbiswas, Arup; Bhargava, Mohan; Jaswal, Aparna; Bhargava, K; Bhatia, Mona; Omar, A K; Khanna, N N; Passey, Rajiv; Bhalla, Dilip; Vijayalakshmi, I B; Bhalla, A K; Moorthy, Asha; Isser, H S; Mishra, S S; Routray, S N; Tandon, Vivek; Sinha, Ajay; Bansal, Manish; Jain, Praveen; Hotchandani, Ramesh; Jain, Dharmendra; Katyal, V K; Gulati, Sanjiv; Tandon, Rohit; Jaggi, Shalini; Sehgal, Blessy; Gupta, Vitull; Mehrotra, Rahul; Krishnamani, N C; Pathak, S N; Yadav, M S; Chawla, Rajeev; Pal, Jyotirmoy; Chatterjee, Nandini; Samajdar, Shambo, S; Shastry, N R.
    Heart failure (HF) is a huge global public health task due to morbidity, mortality, disturbed quality of life, and major economic burden. It is an area of active research and newer treatment strategies are evolving. Recently angiotensin receptor-neprilysin inhibitor (ARNI), a class of drugs (the first agent in this class, Sacubitril–Valsartan), reduces cardiovascular mortality and morbidity in chronic HF patients with reduced left ventricular ejection fraction (LVEF). Positive therapeutic effects have led to a decrease in cardiovascular mortality and HF hospitalizations (HFH), with a favorable safety profile, and have been documented in several clinical studies with an unquestionable survival benefit with ARNI, Sacubitril–Valsartan. This consensus statement of the Indian group of experts in cardiology, nephrology, and diabetes provides a comprehensive review of the power and promise of ARNI in HF management and an evidence-based appraisal of the use of ARNI as an essential treatment strategy for HF patients in clinical practice. Consensus in this review favors an early utility of Sacubitril–Valsartan in patients with HF with reduced EF (HFrEF), regardless of the previous therapy being given. A lower rate of hospitalizations for HF with Sacubitril–Valsartan in HF patients with preserved EF who are phenotypically heterogeneous suggests possible benefits of ARNI in patients having 40–50% of LVEF, frequent subtle systolic dysfunction, and higher hospitalization risk.
  • Thumbnail Image
    Item
    Role of Iron Therapy in Heart Failure: A Consensus Statement from India
    (Association of Physicians of India, 2023-03) Chopra, H K; Wander, G S; Nair, Tiny; Ponde, C K; Nanda, Navin C; Narula, Jagat; Ray, Saumitra; Venugopal, K; Iyengar, S S; Kasliwal, R R; Chandra, Praveen; , Prakash, Sunil; Bansal, Sandeep; Rana, D S; Kerkar, Prafulla; Dasbiswas, Arup; Sawhney, JPS; Shanmungasundram, S; Kumar, Viveka; Vijayalakshmi, I B; Pancholia, A K; Sharma, Vinod; Kapoor, Aditya; Swami, Onkar C; Isser, , S; Rastogi, Vishal; Arora, Y K; Omar, Ashok K; Sathe, Sunil; Rajput, Rajeeve; Prabhakar, D; Paul, G J; Priya, Jagia; Poonam, Malhotra; G, Suryaprakash; Vinod, Mittal; Manish, Jagia; A, Jabir; S, S Mishra; S, N Routray; Ajay, K Sinha; Mohan, Bhargava; Kiran, Mahmood; Bhatia, Mona; Kalra, Pramila; Katyal, V K; Tandon, Rohit; Grover, Rahul; Chhabra, Abhinav; Shastry, N R
    Iron deficiency (ID) with or without anemia is frequently observed in patients with heart failure (HF). Uncorrected ID is associated with higher hospitalization and mortality in patients with acute HF (AHF) and chronic HF (CHF). Hence, in addition to chronic renal insufficiency, anemia, and diabetes, ID appears as a novel comorbidity and a treatment target of CHF. Intravenous (IV) ferric carboxymaltose (FCM) reduces the hospitalization risk due to HF worsening and improves functional capacity and quality of life (QOL) in HF patients. The current consensus document provides criteria, an expert opinion on the diagnosis of ID in HF, patient profiles for IV FCM, and correct administration and monitoring of such patients.